In vitro and in vivo Limiting Dilution Assay for Colorectal Cancer
- 1 January 2015
- journal article
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 5 (22) , e1659
Abstract
The in vitro limiting dilution assay is used to determine the colorectal cancer initiating cell (CC-IC) frequency of a CC-IC enriched suspension culture, grown in growth factor enriched serum free media. The in vivo limiting dilution assay is used to determine the colorectal cancer initiating cell frequency of a primary colorectal cancer sample or an established suspension cell line using immunocompromised murine xenograft models. In vitro and in vivo limiting dilution assays (LDAs) can be used to determine the effect of a specific treatment or genetic knockdown strategy on the initiating cell frequency of a population of CC-ICs or colorectal cancer sample, respectively. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.Keywords
This publication has 4 references indexed in Scilit:
- Self-renewal as a therapeutic target in human colorectal cancerNature Medicine, 2013
- ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assaysJournal of Immunological Methods, 2009
- Limiting dilution assaysJournal of Immunological Methods, 1987
- The evaluation of limiting dilution assaysJournal of Immunological Methods, 1982